Topotecan hydrochloride

Topoisomerase 1 inhibitor CAS# 119413-54-6

Topotecan hydrochloride

Catalog No. BCN2604----Order now to get a substantial discount!

Product Name & Size Price Stock
Topotecan hydrochloride: 5mg $35 In Stock
Topotecan hydrochloride: 10mg Please Inquire In Stock
Topotecan hydrochloride: 20mg Please Inquire Please Inquire
Topotecan hydrochloride: 50mg Please Inquire Please Inquire
Topotecan hydrochloride: 100mg Please Inquire Please Inquire
Topotecan hydrochloride: 200mg Please Inquire Please Inquire
Topotecan hydrochloride: 500mg Please Inquire Please Inquire
Topotecan hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Topotecan hydrochloride

Number of papers citing our products

Chemical structure

Topotecan hydrochloride

3D structure

Chemical Properties of Topotecan hydrochloride

Cas No. 119413-54-6 SDF Download SDF
PubChem ID 60699 Appearance Powder
Formula C23H24ClN3O5 M.Wt 457.9
Type of Compound Alkaloids Storage Desiccate at -20°C
Synonyms SK&F; 104864-A; SKF 104864A; SKFS 104864A; NSC 609669; Nogitecan hydrochloride
Solubility H2O : 50 mg/mL (109.19 mM; Need ultrasonic)
DMSO : 25 mg/mL (54.60 mM; Need ultrasonic)
SMILES CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=C(C5=C4)CN(C)C)O)O.Cl
Standard InChIKey DGHHQBMTXTWTJV-BQAIUKQQSA-N
Standard InChI InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Topotecan hydrochloride

The herbs of Camptotheca acuminata Decne

Biological Activity of Topotecan hydrochloride

DescriptionTopotecan hydrochloride, a topoisomerase I inhibitor, capable of inhibiting tumoral growth in animal models of retinoblastoma. Topotecan hydrochloride liposomes loaded CS/β-GP hydrogel could become a potential formulation for improving the antitumor efficacy of Topotecan hydrochloride.
TargetsTopoisomerase I
In vivo

Topotecan hydrochloride effects on retinal vessels in newborn rats.[Pubmed: 22374727]

Histol Histopathol. 2012 Apr;27(4):497-506.

A physiological system, i.e. rodent retina during vessel formation and hierarchical organization, was utilised for assaying antiangiogenic properties of Topotecan, a topoisomerase I inhibitor, capable of inhibiting tumoral growth in animal models of retinoblastoma. In particular we analysed possible differences in effectiveness and side effects among different drug dosages and ways of administration.
METHODS AND RESULTS:
In the present research only qualitative analyses were undertaken. After preliminary experiments, in which suckling animals subcutaneously treated with Topotecan dosages comprised between 9 and 3 mg/kg underwent high lethality and extremely severe systemic damages, 7 day-old rats were subcutaneously, intravenously or peribulbary injected with a single dose of 1 mg/kg; retinal vessels were visualized in retinal fluorangio-graphies taken 1 and 2 weeks after treatment. The most important and frequent alterations were found to affect radial vessels, which showed non-perfused and/or regionally mislocated segments, together with abnormal branching and enlargements in retinal periphery; persistence of capillary-free periarteriolar regions, non-vascularised regions and spots of extravascular FITC were also detected. Despite the high individual variability the alterations were substantially similar among the different ways of drug administration, while they appeared milder in 21 day-old rats, with respect to younger ones.
CONCLUSIONS:
The extensive vascular remodelling found after Topotecan administration, besides demonstrating the antiangiogenic properties of this chemioterapic drug, confirms the rodent retina as a highly valuable model system for studying angiogenesis modulation.

Protocol of Topotecan hydrochloride

Structure Identification
Pharm Dev Technol. 2014 Jun 9:1-8.

Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.[Pubmed: 24909735]

Topotecan hydrochloride (TPT) has potential for the treatment of ovarian cancer, but the activity of TPT tends to decrease due to the ring-opening at physiological pH.
METHODS AND RESULTS:
In this study, we proposed to incorporate TPT liposomes into injectable thermosensitive in situ hydrogel, consisting of chitosan (CS) and β-glycerophosphate (β-GP), for sustained release and preservation of active lactone form of TPT. The rheology studies were carried out to investigate the sol-gel temperature, flow behavior and viscosity of these CS/β-GP systems. The optimized formulation exhibited sol-gel transition at 40.2 ± 0.4 °C, with pseudoplastic flow behavior. The drug release rate of TPT liposomes loaded CS/β-GP hydrogel in phosphate buffer saline (pH = 7.4) was found to be slowed down, and the lactone fraction of TPT in the hydrogel matrix was maintaining 40% after 50 h. In addition, the antitumor efficacy in Kunming mice bearing Hepatoma-22 tumor, after intratumoral injection of TPT liposomes loaded CS/β-GP hydrogel, was higher than that of TPT in saline and TPT in CS/β-GP hydrogel.
CONCLUSIONS:
Those results demonstrated that TPT liposomes loaded CS/β-GP hydrogel could become a potential formulation for improving the antitumor efficacy of TPT and suggested an important technology platform for intratumoral administration of derivative of camptothecin-family drugs.

Topotecan hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Topotecan hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Topotecan hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1839 mL 10.9194 mL 21.8388 mL 43.6777 mL 54.5971 mL
5 mM 0.4368 mL 2.1839 mL 4.3678 mL 8.7355 mL 10.9194 mL
10 mM 0.2184 mL 1.0919 mL 2.1839 mL 4.3678 mL 5.4597 mL
50 mM 0.0437 mL 0.2184 mL 0.4368 mL 0.8736 mL 1.0919 mL
100 mM 0.0218 mL 0.1092 mL 0.2184 mL 0.4368 mL 0.546 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Topotecan hydrochloride

Topotecan HCl(SKF104864)is an inhibitor of topoisomerase 1 and semisynthetic analogue of camptothecin [1].

Topotecan HCl(SKF104864)has been reported to have a potent antitumor activity against tumors in murine models. In addition, Topotecan HCl has also shown the potent effect against intravenously implanted P388 leukemia and both intravenously and subcutaneously implanted Lewis lung carcinoma. Topotecan HCl has noted the activity against subcutaneously implanted solid tumors including chemorefractory tumors and human colon carcinoma xenograft HT-29. Topotecan HCl has been found to induce regressions in the lung tumor model (Lewis lung carcinoma and B16 melanoma), compared to camptothecin and 9-amino-camptothecin. In the preclinical toxicology studies, Topotecan HCl has been revealed to have a concentration-dependent, reversible and limited toxoicity to rapidly proliferation tissues such as bone marrow and gastro-intestinal epithelium [1].

References:
[1] Creemers GJ1, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev. 1994 Jan;20(1):73-96.

Featured Products
New Products
 

References on Topotecan hydrochloride

Topotecan hydrochloride effects on retinal vessels in newborn rats.[Pubmed:22374727]

Histol Histopathol. 2012 Apr;27(4):497-506.

A physiological system, i.e. rodent retina during vessel formation and hierarchical organization, was utilised for assaying antiangiogenic properties of Topotecan, a topoisomerase I inhibitor, capable of inhibiting tumoral growth in animal models of retinoblastoma. In particular we analysed possible differences in effectiveness and side effects among different drug dosages and ways of administration. In the present research only qualitative analyses were undertaken. After preliminary experiments, in which suckling animals subcutaneously treated with Topotecan dosages comprised between 9 and 3 mg/kg underwent high lethality and extremely severe systemic damages, 7 day-old rats were subcutaneously, intravenously or peribulbary injected with a single dose of 1 mg/kg; retinal vessels were visualized in retinal fluorangio-graphies taken 1 and 2 weeks after treatment. The most important and frequent alterations were found to affect radial vessels, which showed non-perfused and/or regionally mislocated segments, together with abnormal branching and enlargements in retinal periphery; persistence of capillary-free periarteriolar regions, non-vascularised regions and spots of extravascular FITC were also detected. Despite the high individual variability the alterations were substantially similar among the different ways of drug administration, while they appeared milder in 21 day-old rats, with respect to younger ones. The extensive vascular remodelling found after Topotecan administration, besides demonstrating the antiangiogenic properties of this chemioterapic drug, confirms the rodent retina as a highly valuable model system for studying angiogenesis modulation.

Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.[Pubmed:24909735]

Pharm Dev Technol. 2015 Nov;20(7):812-819.

Topotecan hydrochloride (TPT) has potential for the treatment of ovarian cancer, but the activity of TPT tends to decrease due to the ring-opening at physiological pH. In this study, we proposed to incorporate TPT liposomes into injectable thermosensitive in situ hydrogel, consisting of chitosan (CS) and beta-glycerophosphate (beta-GP), for sustained release and preservation of active lactone form of TPT. The rheology studies were carried out to investigate the sol-gel temperature, flow behavior and viscosity of these CS/beta-GP systems. The optimized formulation exhibited sol-gel transition at 40.2 +/- 0.4 degrees C, with pseudoplastic flow behavior. The drug release rate of TPT liposomes loaded CS/beta-GP hydrogel in phosphate buffer saline (pH = 7.4) was found to be slowed down, and the lactone fraction of TPT in the hydrogel matrix was maintaining 40% after 50 h. In addition, the antitumor efficacy in Kunming mice bearing Hepatoma-22 tumor, after intratumoral injection of TPT liposomes loaded CS/beta-GP hydrogel, was higher than that of TPT in saline and TPT in CS/beta-GP hydrogel. Those results demonstrated that TPT liposomes loaded CS/beta-GP hydrogel could become a potential formulation for improving the antitumor efficacy of TPT and suggested an important technology platform for intratumoral administration of derivative of camptothecin-family drugs.

Description

Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.

Keywords:

Topotecan hydrochloride,119413-54-6,SK&F; 104864-A; SKF 104864A; SKFS 104864A; NSC 609669; Nogitecan hydrochloride,Natural Products,Topoisomerase, buy Topotecan hydrochloride , Topotecan hydrochloride supplier , purchase Topotecan hydrochloride , Topotecan hydrochloride cost , Topotecan hydrochloride manufacturer , order Topotecan hydrochloride , high purity Topotecan hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: